Clinical-stage biopharmaceutical company Adocia (Euronext Paris:ADOC) announced on Tuesday that it has filed patent applications for stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone platform.
These combinations, such as CagriSema (cagrilintide and semaglutide), can be administered using standard injection devices, offering convenience and flexibility for patients.
Adocia's innovation addresses the challenge of combining different hormones for more effective obesity treatments. By overcoming compatibility issues, Adocia's BioChaperone platform enables the production of stable formulations that can be administered using existing injection devices. This could significantly improve the accessibility and convenience of these treatments.
Adocia is also researching new peptide combinations for obesity treatment and exploring partnerships to advance these innovations.
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Frost & Sullivan honours Novotech
Turnstone Biologics announces strategic restructuring
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
Novo Holdings launches Booster Therapeutics
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
KeyBioscience extends Eli Lilly collaboration
Tempest to advance amezalpat combination into pivotal trial for HCC
Pharming initiates Phase II clinical trial for leniolisib in PIDs
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Biogen receives FDA Breakthrough Therapy Designation for felzartamab